The decision-making processes of FDA advisory committees play a pivotal role in shaping the regulatory trajectory of drugs, biologics, and medical devices in the United States. These committees, composed of independent experts in clinical medicine, biostatistics, and related disciplines, provide nonbinding recommendations that inform the U.S. Food and Drug Administration’s final determinations. While the FDA … Read more
Fast Track and Breakthrough Therapy designations represent two of the most strategically important expedited pathways within the US drug development framework, both administered by the Food and Drug Administration. While they share a common objective of accelerating therapies for serious conditions, their evidentiary thresholds, regulatory privileges, and commercialisation implications differ in ways that directly impact … Read more
Clinical trial diversity requirements are becoming a central component of regulatory expectations in the United States as the biomedical industry moves into 2026. Historically, clinical research populations have often failed to reflect the demographic composition of the patients who ultimately use approved therapies. In response, regulators, policymakers, and research institutions are strengthening expectations for inclusive … Read more